IASLC Staging and Prognostic Factors Committee Chair Dr. Hisao Asamura and Drs. Valerie Rusch and Enrico Ruffini summarized the data and recommendations in lung cancer, mesothelioma, and thymic cancer. Read more

Dr. Tetsuya Mitsudomi, who presented the data at WCLC 2023, said regardless of disease stage, the addition of perioperative durvalumab did not adversely impact the feasibility, type, approach, or timing of surgery for participants in the trial. Read more

Drs. Mariam Jamal-Hanjani, Alan Sihoe, Anil Tibdewal, and Ross Soo discussed challenges and strategies across the lung cancer spectrum—from early-stage to oligometastatic and advanced disease. Read more

Honorees Drs. Jessica Donington, Rafal Dziadziuszko, and Jie Wang presented thought-provoking talks on return to treatment after surgery, radiation oncology in Poland, and biomarkers in small cell lung cancer. Read more

The IASLC Academy’s 2023 cohort spent months leading up to WCLC 2023 crafting case summaries in hopes of winning a spot in the association’s first case-based simulation course. Read more

Drs. Silvia Novello, Alan Sihoe, and D. Ross Camidge kicked off the session with forward-looking talks on tobacco control and smoking cessation, surgery, and medical oncology. Read more

After more than 2 years, the median duration of response was 12.4 months and no new safety signals were seen, according to Dr. Shirish Gadgeel, who presented the results during WCLC 2023. Read more

Dr. Solange Peters presented new follow-up data from CheckMate 227 that show positive results regardless of PD-L1 expression. Read more

During WCLC 2023, researcher Dr. Kevin Lamote shared data that demonstrated VOCs in exhaled breath could be a useful biomarker. Read more

IASLC leaders also shared highlights from the association’s membership growth and financial report and officially welcomed President Dr. Paul Van Schil. Read more